Pharmaceutical Development Services (PDS) have announced a major extension to their range of consultancy services with the appointment of two new associates, both of whom are experts in the rapidly growing area of medical devices.
Pharmaceutical Development Services Ltd (PDS) has announced a major addition to its front line consultancy team with the appointment of Graham Clapperton to head up PDS quality services.
Pharmaceutical Development Services Ltd (PDS), is expanding its team of associates to meet growing demand and to provide the Active Pharmaceutical Ingredient (API) auditing capability demanded by companies keen to maintain their quality credentials with regulatory authorities.
Huge increase in storage capacity for ambient, cold storage and controlled drugs.
Innovaro (NYSE Amex: INV), a comprehensive innovation solutions company, is pleased to announce that it has facilitated the completion of a licensing transaction between Trojan Technologies USA, a company recently formed by Verdant Ventures Advisors II, LLC (Verdant Ventures), and Trojantec Ltd (heretofore "Trojantec"), a London and Cyprus based biopharmaceutical company.
A friendly and informative IP tool for iPhone / iPad brought to you by The Luzzatto Group was released on 29 May 2010.
Meeting our client partner's commercial need for additional sachet capacity, Almac completes a £2 million investment programme.
MPI Research, the largest single-site preclinical contract research organisation in the world, today announced its global initiative to brand the company as "Your Responsive CRO".
MPI Research, the largest single-site preclinical contract research organisation in the world, has formed a collaboration with Andrew Hendrickx, PhD, a recognised expert in nonhuman primate developmental and reproductive toxicology (DART). As a consultant for the MPI Research nonhuman primate reproduction program, Dr Hendrickx will coach, guide, and participate in the study design and interpretation process.
On 26 January 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalised, this guidance will represent the FDA's current position on the abuse potential of drugs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.